Stem Cell Sources in Islet Cell Research
In islet cell research, stem cells are primarily derived from three main sources: human embryonic stem cells (hESCs) obtained from excess IVF embryos, induced pluripotent stem cells (iPSCs) generated from adult somatic cells (typically skin fibroblasts), and adult stem cells isolated from tissues such as bone marrow, umbilical cord, and placenta 1.
Primary Stem Cell Sources
Human Embryonic Stem Cells (hESCs)
hESCs represent the gold standard for islet cell research and are obtained from:
- Excess embryos discarded after successful IVF procedures
- Previously frozen embryos from earlier IVF cycles
- De novo synthesis
- Embryos with arrested or abnormal growth unsuitable for implantation 1
The isolation process results in embryo destruction, though newer techniques using 1-2 cell biopsies can generate hESC lines without destroying the embryo. However, these biopsy-derived lines still require comparison with traditionally-derived lines to establish equivalency, and embryos undergoing such biopsies are typically not selected for implantation anyway 1.
Once isolated, hESCs are cultured to create self-renewing cell lines that can be maintained indefinitely 1. hESCs remain the scientific gold standard because they are truly pluripotent and can differentiate into all three embryonic germ layers 1.
Induced Pluripotent Stem Cells (iPSCs)
iPSCs are generated by genetically reprogramming adult somatic cells, usually skin fibroblasts, through expression of specific dedifferentiation genes 1. This breakthrough technology, successfully demonstrated in humans in 2007, creates cells capable of differentiating into all three embryonic germ layers 1.
Key advantages of iPSCs:
- Patient-specific cells can be generated, reducing immunologic rejection risk 2
- No embryo destruction required
- Ethically less controversial 3
Important limitations to consider:
- iPSCs retain their "molecular identity" and may be less stable and efficient than hESCs 1
- Increased susceptibility to unregulated growth similar to neoplastic processes, raising cancer concerns 1
- Some iPSCs show gene silencing issues affecting fetal development and differentiation 1
- High level of cellular manipulation creates concerns about in vivo function 1
Despite advances, iPSCs have not replaced hESCs in research 1. Comparative studies using iPSCs still require ongoing access to hESCs as the reference standard 1.
Adult Stem Cells
Adult stem cells can be isolated from multiple tissue sources:
- Bone marrow - the first recognized source, now standard for hematologic malignancies 1
- Umbilical cord and placenta - easily available, noninvasive collection, no ethical constraints, can be extensively expanded while retaining multilineage differentiation potential 3
- Brain, cardiac muscle, connective tissue, and bone 1
Critical distinction: Adult stem cells are NOT pluripotent like hESCs 1. They facilitate tissue growth and repair but have more limited differentiation capacity. However, umbilical cord and placenta-derived mesenchymal stem cells can cross lineage boundaries toward endodermal lineage, making them viable for pancreatic/islet differentiation 3.
Current State of Stem Cell-Derived Islets
Recent protocols have successfully generated functional stem cell-derived islets (SC-islets) from human pluripotent stem cells that:
- Show strong glucose responsiveness in vitro
- Restore normal glycemic control after transplantation in diabetic mice
- Are free of non-endocrine cell populations 4
SC-islets are now showing promising results in early clinical trials 5, 6, addressing the critical shortage of human donor islets that currently limits islet transplantation to less than 0.5% of type 1 diabetics 7.
Common Pitfalls
Do not assume iPSCs have obviated the need for hESCs - while politically appealing, the scientific evidence shows iPSCs have significant limitations in stability, efficiency, and safety compared to hESCs 1.
Recognize that "adult stem cells" from different sources have vastly different properties - bone marrow stem cells differ substantially from umbilical cord-derived mesenchymal stem cells in their differentiation potential 3, 8.